Imprimis Pharmaceuticals Stock Forecast

Buy or Hold candidate since Jun 10, 2026 Gain 17.19%

The Imprimis Pharmaceuticals stock price gained 1.37% on the last trading day (Friday, 26th Jun 2026), rising from $41.50 to $42.07. During the last trading day the stock fluctuated 4.40% from a day low at $40.50 to a day high of $42.28. The price has been going up and down for this period, and there has been a 11.74% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 846 thousand more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately $64.12 million.

The stock lies in the upper part of a very wide and weak rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $42.95 will firstly indicate a stronger rate of rising. Given the current short-term trend, the stock is expected to rise 2.22% during the next 3 months and, with a 90% probability hold a price between $30.15 and $43.90 at the end of this 3-month period.

HROW Signals & Forecast

The Imprimis Pharmaceuticals stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $42.32. On a fall, the stock will find some support from the long-term average at approximately $35.81. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, June 18, 2026, and so far it has fallen -1.87%. Further fall is indicated until a new bottom pivot has been found.

Support, Risk & Stop-loss for Imprimis Pharmaceuticals stock

Imprimis Pharmaceuticals finds support from accumulated volume at $41.50 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.78 between high and low, or 4.40%. For the last week, the stock has had daily average volatility of 4.43%.

The Imprimis Pharmaceuticals stock is overbought on RSI14 and lies in the upper part of the trend. Normally this may pose a good selling opportunity for the short-term trader, but some stocks may go long and hard while being overbought. Regardless, the high RSI together with the trend position increases the risk and higher daily movements (volatility) should be expected. A correction down in the nearby future seems very likely and it is of great importance that the stock manages to break the trend before that occurs.

Our recommended stop-loss: $40.43 (-3.90%) (This stock has high daily movements and this gives high risk. The RSI14 is 83 and this increases the risk substantially. There is a sell signal from a pivot top found 5 days ago.)

Trading Expectations (HROW) For The Upcoming Trading Day Of Monday 29th

For the upcoming trading day on Monday, 29th we expect Imprimis Pharmaceuticals to open at $41.62, and during the day (based on 14 day Average True Range), to move between $41.05 and $43.09, which gives a possible trading interval of +/-$2.03 (+/-4.95%) up or down from last closing price. If Imprimis Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 4.95% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $42.41 (0.81%) than the support at $41.50 (1.35%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Imprimis Pharmaceuticals stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Imprimis Pharmaceuticals stock to perform well in the short-term.

Current score: 3.711 Buy Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 29, 2026 - $41.62 ( 1.08%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk